A Phase 2 interventional study of LY2439821 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 75 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-26.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 13th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 2, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Germany
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 448 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 164 across the 35 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA):
Study I1F-MC-RHAK is a multicenter study in participants with active RA on concomitant conventional DMARD therapy. The study is a Phase 2 study with 2 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design and Part B is an optional, open-label extension design. Two participant populations will be evaluated in this study: bDMARD-naive participants and TNFα-IR participants. Participants in Part A receive multiple subcutaneous injections of LY2439821 [bDMARD-naive participants: 0 (placebo), 3, 10, 30, 80, or 180 mg; TNFα-IR participants: 0 (placebo), 80 or 180 mg] at Weeks 0, 1, 2, 4, 6, 8, and 10. Participants in Part B receive subcutaneous injections of LY2439821 160 mg at Weeks 16, 18, and 20, and every 4 weeks thereafter through Week 60. Participants who complete both Part A and B have a total study participation of up to approximately 72 to 84 weeks.
Inclusion Criteria:
Qualifications Specific to the bDMARD-naive Population:
You must be regularly using methotrexate (MTX) for at least 12 weeks before your participation in this study
Qualifications Specific to the TNFα-IR Population:
Exclusion Criteria:
Exclusions Specific to the bDMARD-naive Population:
Exclusions Specific to the TNFα-IR Population:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)\]
Biological: LY2439821
10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Biological: LY2439821
30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Biological: LY2439821
80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Biological: LY2439821
180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Biological: LY2439821
80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)\]
Biological: LY2439821
180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Biological: LY2439821
Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Drug: Placebo
Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
Drug: Placebo
Subcutaneous
Also known as: ixekizumab
Subcutaneous
Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.
Time frame: Week 12
Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population
ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.
Time frame: Week 12
Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population
ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.
Time frame: Week 12
Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population
DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 - CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96.
Time frame: Week 12
Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population
ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.
Time frame: Week 12
Change From Baseline in Disease Activity Score (DAS28)-Part A
DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.
Time frame: Baseline, up to Week 12
Change From Baseline in DAS28 - Part B
DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.
Time frame: Baseline, Week 64
Percentage of Participants With ACR20/50/70 Response - Part A
ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100.
Time frame: Week 12
Percentage of Participants With of ACR20/50/70 Response - Part B
ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100\].
Time frame: Week 64
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A
TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B
TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.
Time frame: Baseline, Week 64
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A
SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B
SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.
Time frame: Baseline, Week 64
Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A
Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain." The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B
Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain". The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.
Time frame: Baseline, Week 64
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A
The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B
The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.
Time frame: Baseline, Week 64
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A
The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B
The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.
Time frame: Baseline, Week 64
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A
CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.
Time frame: Baseline, up to Week 12
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B
CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.
Time frame: Baseline, Week 64
Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A
Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.
Time frame: Week 12
Percentage of Participants in EULAR28 - Part B
Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.
Time frame: Week 64
ACR-N - Part A
ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value) / baseline value\] \* 100.
Time frame: Week 12
ACR-N - Part B
ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value)/baseline value\] \* 100.
Time frame: Week 64
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A
The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.
Time frame: Baseline, up to Week 12
Change From Baseline in FACIT Fatigue Scale - Part B
The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.
Time frame: Baseline, Week 64
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A
The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.
Time frame: Baseline, up to Week 12
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B
The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.
Time frame: Baseline, Week 64
Change From Baseline in HAQ-DI - Part A
HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.
Time frame: Baseline, up to Week 12
Change From Baseline in HAQ-DI - Part B
HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.
Time frame: Baseline, Week 64
Relationship Between Exposure and Response of Individual Components of the ACR Core Set
Time frame: Through Week 72
Relationship Between Exposure and Response of ACR20/50/70/N
Time frame: Through Week 72
Relationship Between Exposure and Response of DAS28
Time frame: Through Week 72
Relationship Between Exposure and Response of EULAR28
Time frame: Through Week 72
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State
Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).
Time frame: Predose: Day 0, Day 1 or 2 or 3, Day 7, Weeks 6, 10, 16, 40 and 64 and Postdose: Day 0 and Week 6
Percentage of Participants With Anti-LY2439821 Antibodies
Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.
Time frame: Week 16, Week 64
| Milestone | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population] | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] |
|---|---|---|---|---|---|---|---|---|---|
| Started | 54 | 40 | 35 | 37 | 57 | 37 | 64 | 65 | 59 |
| Received ≥1 doses of study drug | 54 | 40 | 35 | 37 | 57 | 37 | 64 | 65 | 59 |
| Completed | 48 | 36 | 33 | 34 | 52 | 33 | 52 | 58 | 51 |
| Not completed | 6 | 4 | 2 | 3 | 5 | 4 | 12 | 7 | 8 |
| Withdrew: Adverse event | 2 | 1 | 0 | 1 | 0 | 1 | 0 | 3 | 3 |
| Withdrew: Entry criteria | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 1 | 3 | 0 | 5 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
| Milestone | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population] | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] |
|---|---|---|---|---|---|---|---|---|---|
| Started | 46 | 36 | 33 | 34 | 51 | 32 | 51 | 57 | 50 |
| Completed | 41 | 33 | 27 | 31 | 44 | 26 | 29 | 38 | 32 |
| Not completed | 5 | 3 | 6 | 3 | 7 | 6 | 22 | 19 | 18 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 1 | 0 | 5 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 1 | 2 | 3 | 12 | 9 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 2 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 1 | 2 | 1 | 4 | 5 | 5 |
| Withdrew: Entry criteria | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.
| percentage of participants | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) |
|---|---|---|---|---|---|---|
| Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population | 34.1 | 46.2 | 52.2 | 55.0 | 55.3 | 54.0 |
ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.
| percentage of participants | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|
| Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population | 23.4 | 40.0 | 39.0 |
ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.
| log (dose) mg | 3 mg to 180 mg LY2439821 (bDMARD-naive Population) |
|---|---|
| Estimated dose to achieve 10% response | 0.8 |
| Estimated dose to achieve 50% response | 2.4 |
| Estimated dose to achieve 90% response | 13.8 |
DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 - CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96.
| log (dose) mg | 3 mg to 180 mg (bDMARD-naive Population) |
|---|---|
| Estimated dose to achieve 10% response | 7.3 |
| Estimated dose to achieve 50 % response | 41.5 |
| Estimated dose to achieve 90% response | 97.0 |
ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.
| log (dose) mg | 3 mg to 180 mg LY2439821 (bDMARD-naive Population) |
|---|---|
| Estimated dose to achieve 10% response | 7.3 |
| Estimated dose to achieve 50% response | 37.9 |
| Estimated dose to achieve 90% response | 81.2 |
DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.
| units on a scale | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28)-Part A | -0.818 ± 0.981 | -1.308 ± 1.092 | -1.565 ± 1.440 | -1.671 ± 1.193 | -1.686 ± 1.344 | -1.940 ± 1.152 | -0.619 ± 1.109 | -1.310 ± 1.303 | -1.571 ± 1.261 |
DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.
| units on a scale | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821(bDMARD-naive Population) | 10 mg/160 mg LY2439821(bDMARD-naive Population) | 30 mg/160 mg LY2439821(bDMARD-naive Population) | 80 mg/160 mg LY2439821(bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821(TNFα-IR Population) | 80 mg/160 mg LY2439821(TNFα-IR Population) | 180 mg/160 mg LY2439821(TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in DAS28 - Part B | -2.143 ± 1.177 | -1.832 ± 1.031 | -2.320 ± 1.292 | -2.277 ± 1.337 | -2.280 ± 1.316 | -2.475 ± 1.140 | -1.740 ± 1.460 | -1.604 ± 1.282 | -1.874 ± 1.279 |
ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100.
| percentage of participants | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| ACR20 | 35.2 | 45.0 | 42.9 | 70.3 | 50.9 | 54.1 | 23.4 | 40.0 | 39.0 |
| ACR50 | 9.3 | 17.5 | 28.6 | 29.7 | 26.3 | 27.0 | 7.8 | 20.0 | 16.9 |
| ACR70 | 1.9 | 5.0 | 14.3 | 13.5 | 7.0 | 13.5 | 3.1 | 3.1 | 10.2 |
ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100\].
| percentage of participants | Placebo/160 mg LY2439821(bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821(TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| ACR20 | 75.0 | 65.6 | 67.9 | 80.6 | 72.7 | 80.8 | 51.6 | 43.9 | 64.7 |
| ACR50 | 42.5 | 37.5 | 50.0 | 48.4 | 47.7 | 61.5 | 32.3 | 22.0 | 38.2 |
| ACR70 | 17.5 | 12.5 | 32.1 | 22.6 | 11.4 | 30.8 | 19.4 | 9.8 | 17.6 |
TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.
| tender joints | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A | -2.95 ± 5.20 | -6.02 ± 7.35 | -6.79 ± 7.67 | -7.05 ± 6.28 | -7.66 ± 8.96 | -8.96 ± 7.47 | -2.96 ± 6.31 | -6.02 ± 7.31 | -6.02 ± 6.74 |
TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.
| tender joints | Placebo/160 mg LY2439821(bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821(TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B | -8.73 ± 6.85 | -8.78 ± 5.32 | -11.43 ± 6.54 | -9.55 ± 6.20 | -10.86 ± 7.48 | -10.55 ± 7.11 | -6.62 ± 8.39 | -7.35 ± 6.83 | -6.81 ± 6.11 |
SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.
| swollen joints | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A | -2.69 ± 6.07 | -4.25 ± 5.58 | -6.51 ± 7.65 | -6.16 ± 6.44 | -7.49 ± 7.98 | -6.52 ± 6.62 | -1.69 ± 5.93 | -5.57 ± 5.51 | -5.15 ± 5.65 |
SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.
| swollen joints | Placebo/160 mg LY2439821(bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821(TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B | -7.25 ± 6.15 | -5.73 ± 4.95 | -9.06 ± 5.92 | -7.26 ± 5.73 | -8.95 ± 6.64 | -8.96 ± 6.06 | -7.32 ± 6.45 | -5.46 ± 6.51 | -6.29 ± 5.75 |
Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain." The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.
| mm | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A | -14.8 ± 23.7 | -18.7 ± 22.8 | -21.3 ± 28.4 | -29.8 ± 24.1 | -25.8 ± 23.0 | -25.3 ± 27.5 | -9.4 ± 24.0 | -10.3 ± 24.7 | -18.8 ± 26.6 |
Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain". The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.
| mm | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B | -32.5 ± 27.8 | -26.2 ± 20.3 | -33.3 ± 33.4 | -36.2 ± 27.4 | -32.4 ± 22.6 | -41.2 ± 23.0 | -25.5 ± 22.3 | -16.5 ± 21.1 | -26.2 ± 26.2 |
The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.
| mm | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A | -19.2 ± 21.4 | -17.3 ± 20.9 | -18.5 ± 28.7 | -29.1 ± 23.1 | -22.1 ± 23.7 | -30.1 ± 26.9 | -10.1 ± 24.7 | -12.1 ± 27.9 | -21.6 ± 25.4 |
The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.
| mm | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B | -35.4 ± 26.2 | -24.9 ± 25.4 | -31.8 ± 30.4 | -34.8 ± 27.0 | -28.5 ± 24.7 | -39.8 ± 25.5 | -22.4 ± 23.2 | -17.8 ± 21.4 | -25.1 ± 23.9 |
The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.
| mm | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A | -16.0 ± 19.0 | -21.0 ± 15.6 | -21.7 ± 25.2 | -26.7 ± 18.1 | -24.5 ± 22.3 | -28.8 ± 24.2 | -8.6 ± 21.4 | -25.7 ± 22.2 | -22.0 ± 24.0 |
The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.
| mm | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B | -36.1 ± 21.7 | -30.1 ± 22.0 | -38.5 ± 28.4 | -38.0 ± 18.5 | -31.0 ± 20.7 | -44.4 ± 17.7 | -30.1 ± 22.5 | -28.9 ± 25.8 | -32.7 ± 25.2 |
CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.
| mg/L | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A | -1.575 ± 22.336 | -6.079 ± 10.289 | -9.435 ± 23.148 | -7.999 ± 14.740 | -11.968 ± 19.792 | -13.575 ± 25.692 | 1.229 ± 14.811 | -9.521 ± 20.312 | -8.297 ± 21.955 |
CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.
| mg/L | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B | -10.548 ± 18.555 | -4.556 ± 12.937 | -11.340 ± 23.347 | -7.865 ± 22.607 | -14.519 ± 19.260 | -6.860 ± 16.745 | -12.094 ± 28.917 | -10.130 ± 18.030 | -9.004 ± 19.698 |
Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.
| percentage of participants | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population]) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A | 44.4 | 67.5 | 60.0 | 75.7 | 73.2 | 75.7 | 36.5 | 60.0 | 65.5 |
Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.
| percentage of participants | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in EULAR28 - Part B | 90.2 | 81.8 | 82.1 | 83.9 | 84.1 | 88.5 | 64.5 | 73.2 | 69.7 |
ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value) / baseline value\] \* 100.
| units on a scale | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821(bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| ACR-N - Part A | -11.034 ± 104.809 | -0.699 ± 139786 | 15.162 ± 51.130 | 11.137 ± 128.516 | 18.351 ± 41.493 | 23.375 ± 42.173 | -7.356 ± 45.724 | 2.264 ± 59.277 | 11.541 ± 49.358 |
ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value)/baseline value\] \* 100.
| units on a scale | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821 (bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| ACR-N - Part B | 36.839 ± 42.241 | 33.154 ± 32.439 | 39.922 ± 37.930 | 34.847 ± 69.410 | 38.996 ± 30.715 | 49.152 ± 31.544 | 22.230 ± 54.682 | 14.389 ± 45.461 | 30.891 ± 41.415 |
The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.
| units on a scale | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821(bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A | 5.566 ± 9.168 | 5.725 ± 8.706 | 6.057 ± 13.512 | 8.924 ± 9.469 | 7.250 ± 9.245 | 5.838 ± 7.946 | 4.953 ± 9.152 | 4.400 ± 8.068 | 6.627 ± 8.401 |
The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.
| units on a scale | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in FACIT Fatigue Scale - Part B | 8.390 ± 8.405 | 4.879 ± 10.810 | 8.500 ± 12.880 | 9.177 ± 11.637 | 7.295 ± 10.436 | 6.038 ± 9.986 | 8.323 ± 9.304 | 4.341 ± 8.493 | 6.647 ± 9.639 |
The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.
| minutes | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821(bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A | -36.6 ± 123.7 | -24.3 ± 87.3 | -52.7 ± 142.0 | -71.4 ± 143.9 | -63.0 ± 57.0 | -69.0 ± 64.1 | -36.3 ± 137.7 | -62.0 ± 138.1 | -43.1 ± 116.7 |
The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.
| minutes | Placebo/160 mg LY2439821(bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B | -92.1 ± 111.3 | -70.2 ± 112.3 | -55.6 ± 72.9 | -92.3 ± 136.7 | -68.8 ± 72.5 | -82.3 ± 79.2 | -61.3 ± 161.9 | -60.9 ± 164.7 | -85.9 ± 74.8 |
HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.
| units on a scale | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821(bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in HAQ-DI - Part A | -0.220 ± 0.459 | -0.322 ± 0.493 | -0.418 ± 0.693 | -0.537 ± 0.639 | -0.469 ± 0.517 | -0.476 ± 0.655 | -0.182 ± 0.458 | -0.223 ± 0.448 | -0.265 ± 0.496 |
HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.
| units on a scale | Placebo/160 mg LY2439821 (bDMARD-naive Population) | 3 mg/160 mg LY2439821 (bDMARD-naive Population) | 10 mg/160 mg LY2439821 (bDMARD-naive Population) | 30 mg/160 mg LY2439821 (bDMARD-naive Population) | 80 mg/160 mg LY2439821 (bDMARD-naive Population) | 180 mg/160 mg LY2439821 (bDMARD-naive Population) | Placebo/160 mg LY2439821 (TNFα-IR Population) | 80 mg/160 mg LY2439821 (TNFα-IR Population) | 180 mg/160 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in HAQ-DI - Part B | -0.616 ± 0.609 | -0.542 ± 0.611 | -0.665 ± 0.662 | -0.673 ± 0.705 | -0.554 ± 0.614 | -0.697 ± 0.571 | -0.331 ± 0.449 | -0.250 ± 0.460 | -0.309 ± 0.437 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).
| nanograms per milliliter (ng/mL) | Part A: 3 mg LY2439821 (bDMARD-naive Population) | Part A: 10 mg LY2439821 (bDMARD-naive Population) | Part A: 30 mg LY2439821 (bDMARD-naive Population) | Part A: 80 mg LY2439821 (bDMARD-naive Population) | Part A: 180 mg LY2439821(bDMARD-naive Population) | Part A: 80 mg LY2439821 (TNFα-IR Population) | Part A: 180 mg LY2439821 (TNFα-IR Population) | Part B: 160 mg LY2439821 (bDMARD-naive and TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State | 336 (138 to 783) | 1060 (352 to 2580) | 3230 (1140 to 7970) | 7580 (2590 to 18600) | 17100 (6870 to 42000) | 7320 (2740 to 17700) | 16200 (6040 to 40600) | 18600 (8040 to 45000) |
Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.
| percentage of participants | Placebo (bDMARD-naive Population) | 3 mg LY2439821 (bDMARD-naive Population) | 10 mg LY2439821 (bDMARD-naive Population) | 30 mg LY2439821 (bDMARD-naive Population) | 80 mg LY2439821 (bDMARD-naive Population) | 180 mg LY2439821(bDMARD-naive Population) | Placebo (TNFα-IR Population) | 80 mg LY2439821 (TNFα-IR Population) | 180 mg LY2439821 (TNFα-IR Population) |
|---|---|---|---|---|---|---|---|---|---|
| Part A Week 16 (n=43,35,34,35,49,33,52,57,51) | 11.6 | 14.3 | 8.8 | 8.6 | 16.3 | 15.2 | 7.7 | 10.5 | 13.7 |
| Part B Week 64 (n=37,32,28,30,40,26,31,41,33) | 0.0 | 0.0 | 3.6 | 0.0 | 2.5 | 3.8 | 6.5 | 0.0 | 9.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mg LY2439821 (bDMARD-naive Population) Part A | — | 0/40 (0%) | 16/40 (40%) |
| 10 mg LY2439821 (bDMARD-naive Population) Part A | — | 1/35 (2.9%) | 16/35 (45.7%) |
| 30 mg LY2439821 (bDMARD-naive Population) Part A | — | 1/37 (2.7%) | 16/37 (43.2%) |
| 80 mg LY2439821 (bDMARD-naive Population) Part A | — | 4/57 (7%) | 23/57 (40.4%) |
| 180 mg LY2439821(bDMARD-naive Population) Part A | — | 1/37 (2.7%) | 16/37 (43.2%) |
| Placebo (bDMARD-naive Population) Part A | — | 1/54 (1.9%) | 22/54 (40.7%) |
| 80 mg LY2439821 (TNFa-IR Population) Part A | — | 5/65 (7.7%) | 31/65 (47.7%) |
| 180 mg LY2439821 (TNFa-IR Population) Part A | — | 6/59 (10.2%) | 32/59 (54.2%) |
| Placebo (TNFa-IR Population) Part A | — | 1/64 (1.6%) | 32/64 (50%) |
| 3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 3/36 (8.3%) | 14/36 (38.9%) |
| 10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 3/33 (9.1%) | 19/33 (57.6%) |
| 30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 2/34 (5.9%) | 12/34 (35.3%) |
| 80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 4/51 (7.8%) | 23/51 (45.1%) |
| 180 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 1/32 (3.1%) | 16/32 (50%) |
| Placebo/160 mg LY2439821 (bDMARD-naive Population) Part B | — | 4/46 (8.7%) | 26/46 (56.5%) |
| 80 mg/160 mg LY2439821 (TNFa-IR Population) Part B | — | 7/57 (12.3%) | 23/57 (40.4%) |
| 180 mg/160 mg LY2439821 (TNFa-IR Population) Part B | — | 4/50 (8%) | 16/50 (32%) |
| Placebo/160 mg LY2439821 (TNFa-IR Population) Part B | — | 7/51 (13.7%) | 23/51 (45.1%) |
| Event | 3 mg LY2439821 (bDMARD-naive Population) Part A | 10 mg LY2439821 (bDMARD-naive Population) Part A | 30 mg LY2439821 (bDMARD-naive Population) Part A | 80 mg LY2439821 (bDMARD-naive Population) Part A | 180 mg LY2439821(bDMARD-naive Population) Part A | Placebo (bDMARD-naive Population) Part A | 80 mg LY2439821 (TNFa-IR Population) Part A | 180 mg LY2439821 (TNFa-IR Population) Part A | Placebo (TNFa-IR Population) Part A | 3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 180 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | Placebo/160 mg LY2439821 (bDMARD-naive Population) Part B | 80 mg/160 mg LY2439821 (TNFa-IR Population) Part B | 180 mg/160 mg LY2439821 (TNFa-IR Population) Part B | Placebo/160 mg LY2439821 (TNFa-IR Population) Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MeningitisInfections and infestations | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 0/33 | 0/34 | 0/51 | 1/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Pancreatitis acuteGastrointestinal disorders | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 1/33 | 1/34 | 0/51 | 0/32 | 0/46 | 1/57 | 0/50 | 0/51 |
| DeathGeneral disorders | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 1/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Urinary tract infectionInfections and infestations | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 1/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Aortic aneurysmVascular disorders | 0/40 | 1/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 1/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| PneumoniaInfections and infestations | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 1/65 | 0/59 | 0/64 | 0/36 | 0/33 | 1/34 | 1/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| PneumoconiosisInjury, poisoning and procedural complications | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 0/36 | 0/33 | 1/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Pyelonephritis acuteInfections and infestations | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 1/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Femur fractureInjury, poisoning and procedural complications | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 1/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Intracranial aneurysmNervous system disorders | 0/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 0/65 | 0/59 | 0/64 | 1/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Event | 3 mg LY2439821 (bDMARD-naive Population) Part A | 10 mg LY2439821 (bDMARD-naive Population) Part A | 30 mg LY2439821 (bDMARD-naive Population) Part A | 80 mg LY2439821 (bDMARD-naive Population) Part A | 180 mg LY2439821(bDMARD-naive Population) Part A | Placebo (bDMARD-naive Population) Part A | 80 mg LY2439821 (TNFa-IR Population) Part A | 180 mg LY2439821 (TNFa-IR Population) Part A | Placebo (TNFa-IR Population) Part A | 3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | 180 mg/160 mg LY2439821 (bDMARD-naive Population) Part B | Placebo/160 mg LY2439821 (bDMARD-naive Population) Part B | 80 mg/160 mg LY2439821 (TNFa-IR Population) Part B | 180 mg/160 mg LY2439821 (TNFa-IR Population) Part B | Placebo/160 mg LY2439821 (TNFa-IR Population) Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/7 | 0/8 | 0/6 | 0/5 | 0/7 | 0/7 | 0/8 | 0/8 | 0/9 | 0/7 | 0/8 | 0/5 | 0/5 | 0/7 | 1/6 | 0/8 | 0/5 | 0/6 |
| NasopharyngitisInfections and infestations | 2/40 | 2/35 | 0/37 | 3/57 | 3/37 | 3/54 | 3/65 | 1/59 | 4/64 | 3/36 | 4/33 | 3/34 | 2/51 | 3/32 | 5/46 | 6/57 | 1/50 | 1/51 |
| Injection site painGeneral disorders | 1/40 | 1/35 | 1/37 | 2/57 | 2/37 | 1/54 | 6/65 | 7/59 | 3/64 | 1/36 | 1/33 | 1/34 | 2/51 | 0/32 | 4/46 | 0/57 | 1/50 | 5/51 |
| HeadacheNervous system disorders | 0/40 | 4/35 | 2/37 | 2/57 | 1/37 | 6/54 | 7/65 | 2/59 | 5/64 | 1/36 | 1/33 | 0/34 | 2/51 | 1/32 | 2/46 | 2/57 | 2/50 | 3/51 |
| Upper respiratory tract infectionInfections and infestations | 1/40 | 0/35 | 3/37 | 3/57 | 2/37 | 0/54 | 4/65 | 6/59 | 7/64 | 0/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/40 | 0/35 | 1/37 | 0/57 | 0/37 | 0/54 | 1/65 | 1/59 | 0/64 | 0/36 | 0/33 | 2/34 | 3/51 | 3/32 | 2/46 | 0/57 | 1/50 | 2/51 |
| Injection site erythemaGeneral disorders | 2/40 | 0/35 | 0/37 | 0/57 | 0/37 | 0/54 | 3/65 | 5/59 | 2/64 | 2/36 | 2/33 | 0/34 | 2/51 | 0/32 | 1/46 | 3/57 | 4/50 | 3/51 |
| Injection site haematomaGeneral disorders | 0/40 | 0/35 | 0/37 | 1/57 | 0/37 | 0/54 | 1/65 | 5/59 | 0/64 | 0/36 | 0/33 | 0/34 | 0/51 | 0/32 | 1/46 | 0/57 | 0/50 | 1/51 |
| Urinary tract infectionInfections and infestations | 1/40 | 2/35 | 3/37 | 2/57 | 2/37 | 4/54 | 4/65 | 5/59 | 2/64 | 0/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/40 | 2/35 | 2/37 | 2/57 | 0/37 | 1/54 | 3/65 | 5/59 | 2/64 | 0/36 | 0/33 | 0/34 | 0/51 | 0/32 | 0/46 | 0/57 | 0/50 | 0/51 |
Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 45 | 37 | 30 | 29 | 48 | 32 | 59 | 55 | 52 | 387 |
| >=65 years | 9 | 3 | 5 | 8 | 9 | 5 | 5 | 10 | 7 | 61 |
| Age, Continuous(years) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.99 ± 10.18 | 52.19 ± 9.67 | 53.86 ± 10.62 | 53.03 ± 12.16 | 52.60 ± 10.91 | 52.21 ± 11.33 | 53.19 ± 10.44 | 54.74 ± 11.12 | 52.43 ± 9.90 | 53.08 ± 10.61 |
| Sex: Female, Male(Participants) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 47 | 33 | 27 | 31 | 52 | 30 | 55 | 57 | 51 | 383 |
| Male | 7 | 7 | 8 | 6 | 5 | 7 | 9 | 8 | 8 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 7 | 8 | 7 | 10 | 6 | 15 | 23 | 15 | 100 |
| Not Hispanic or Latino | 45 | 32 | 24 | 29 | 46 | 30 | 48 | 41 | 43 | 338 |
| Unknown or Not Reported | 0 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 3 | 2 | 1 | 2 | 4 | 0 | 0 | 2 | 16 |
| Asian | 16 | 13 | 10 | 12 | 17 | 10 | 3 | 4 | 3 | 88 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 0 | 1 | 3 | 1 | 6 | 2 | 4 | 23 |
| White | 29 | 20 | 21 | 20 | 31 | 22 | 54 | 58 | 50 | 305 |
| More than one race | 3 | 2 | 2 | 3 | 4 | 0 | 1 | 1 | 0 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo [bDMARD-naive Population] | 3 mg LY2439821 [bDMARD-naive Population] | 10 mg LY2439821 [bDMARD-naive Population] | 30 mg LY2439821 [bDMARD-naive Population | 80 mg LY2439821 [bDMARD-naive Population] | 180 mg LY2439821[bDMARD-naive Population] | Placebo [TNFα-IR Population] | 80 mg LY2439821 [TNFα-IR Population] | 180 mg LY2439821 [TNFα-IR Population] | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 12 | 9 | 8 | 8 | 12 | 9 | 33 | 32 | 31 | 154 |
| Taiwan | 5 | 4 | 3 | 4 | 4 | 3 | 1 | 1 | 1 | 26 |
| Argentina | 1 | 0 | 0 | 1 | 1 | 0 | 10 | 11 | 10 | 34 |
| Poland | 11 | 8 | 8 | 7 | 9 | 7 | 11 | 11 | 10 | 82 |
| Romania | 5 | 4 | 3 | 4 | 6 | 3 | 1 | 1 | 0 | 27 |
| Peru | 6 | 4 | 4 | 4 | 6 | 4 | 1 | 1 | 1 | 31 |
| Chile | 0 | 1 | 2 | 0 | 2 | 2 | 1 | 2 | 1 | 11 |
| Russian Federation | 3 | 1 | 0 | 1 | 3 | 2 | 1 | 1 | 1 | 13 |
| Germany | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 2 | 2 | 8 |
| Korea, Republic of | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 16 |
| India | 9 | 7 | 6 | 7 | 11 | 6 | 0 | 0 | 0 | 46 |
The record gives a start of Aug 2009, a primary completion of Mar 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 5 years 2 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab